Sloane Bonnie F, Sameni Mansoureh, Podgorski Izabela, Cavallo-Medved Dora, Moin Kamiar
Department of Pharmacology, School of Medicine, Wayne State University, Detroit, MI 48201, USA.
Annu Rev Pharmacol Toxicol. 2006;46:301-15. doi: 10.1146/annurev.pharmtox.45.120403.095853.
The roles of proteases in cancer are now known to be much broader than simply degradation of extracellular matrix during tumor invasion and metastasis. Furthermore, proteases from tumor-associated cells (e.g., fibroblasts, inflammatory cells, endothelial cells) as well as tumor cells are recognized to contribute to pathways critical to neoplastic progression. Although elevated expression (transcripts and proteins) of proteases, and in some cases protease inhibitors, has been documented in many tumors, techniques to assess functional roles for proteases require that we measure protease activity and inhibition of that activity rather than levels of proteases, activators, and inhibitors. Novel techniques for functional imaging of protease activity, both in vitro and in vivo, are being developed as are imaging probes that will allow us to determine protease activity and in some cases to discriminate among protease activities. These should be useful clinically as surrogate endpoints for therapies that alter protease activities.
现在已知蛋白酶在癌症中的作用远比肿瘤侵袭和转移过程中简单的细胞外基质降解更为广泛。此外,来自肿瘤相关细胞(如成纤维细胞、炎症细胞、内皮细胞)以及肿瘤细胞的蛋白酶被认为对肿瘤进展的关键途径有贡献。尽管在许多肿瘤中已记录到蛋白酶以及某些情况下蛋白酶抑制剂的表达升高(转录本和蛋白质),但评估蛋白酶功能作用的技术要求我们测量蛋白酶活性以及对该活性的抑制,而非蛋白酶、激活剂和抑制剂的水平。正在开发用于体外和体内蛋白酶活性功能成像的新技术,以及能让我们确定蛋白酶活性并在某些情况下区分不同蛋白酶活性的成像探针。这些在临床上作为改变蛋白酶活性疗法的替代终点应该会很有用。